Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

R Pirker, JR Pereira, A Szczesna, J von Pawel… - The Lancet, 2009 - thelancet.com
Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor
receptor (EGFR), has the potential to increase survival in patients with advanced non-small …
被引用次数：1834 相关文章

[引用][C] Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

R Pirker, J Pereira, A Szczesna, J von Pawel… - …, 2009 - researchnow.flinders.edu.au
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an
open-label randomised phase III trial — Research @ Flinders Skip to main navigation Skip to …

[引用][C] Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

R PIRKER - Lancet, 2009 - cir.nii.ac.jp
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX) : an
open-label randomised phase III trial | CiNii Research CiNii 国立情報学研究所 学術情報 …

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

R Pirker, JR Pereira, A Szczesna, J von Pawel… - The Lancet, 2009 - infona.pl
Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor
(EGFR), has the potential to increase survival in patients with advanced non-small-cell lung …

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

R Pirker, JR Pereira, A Szczesna… - Lancet (London …, 2009 - pubmed.ncbi.nlm.nih.gov
Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor
receptor (EGFR), has the potential to increase survival in patients with advanced non-small …

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

R Pirker, JR Pereira, A Szczesna, J von Pawel… - The …, 2009 - dial.uclouvain.be
BACKGROUND: Use of cetuximab, a monoclonal antibody targeting the epidermal growth
factor receptor (EGFR), has the potential to increase survival in patients with advanced non …

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

R Pirker, JR Pereira, A Szczesna, J von Pawel… - The Lancet, 2009 - Elsevier
BACKGROUND: Use of cetuximab, a monoclonal antibody targeting the epidermal growth
factor receptor (EGFR), has the potential to increase survival in patients with advanced non …

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

R Pirker, JR Pereira, A Szczesna, J von Pawel… - The Lancet, 2009 - elibrary.ru
Background: Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor
receptor (EGFR), has the potential to increase survival in patients with advanced non-small …

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

R Pirker, JR Pereira, A Szczesna, J von Pawel… - 2009 - mediatum.ub.tum.de
BACKGROUND: Use of cetuximab, a monoclonal antibody targeting the epidermal growth
factor receptor (EGFR), has the potential to increase survival in patients with advanced non …
[PDF] academia.edu

[PDF][PDF] Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

R Pirker, JR Pereira, A Szczesna, J von Pawel… - Lancet, 2009 - academia.edu
Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor
receptor (EGFR), has the potential to increase survival in patients with advanced non-small …